Perspective from R.V. Paul Chan, MD, FACS
February 25, 2017
2 min read

Anti-VEGF used as primary or adjunctive treatment for ROP

Perspective from R.V. Paul Chan, MD, FACS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

FORT LAUDERDALE, Fla. — Anti-VEGF therapy can be used to treat retinopathy of prematurity as a primary treatment, as a complementary treatment to laser and as an adjunct in vitreoretinal surgery, according to a speaker here.

“Our current management of ROP considers the use of anti-VEGF as primary treatment depending on the zone of the disease and as an adjunct in progressive cases,” Paola Dorta, MD, of Santiago, Chile, reported at the Retina World Congress.

Paola Dorta

Paola Dorta

For type 1 retinopathy of prematurity (ROP), Dorta said intravitreal bevacizumab can be used as a firstline therapy. In a study by Dorta and colleagues, 12 eyes of seven patients with type 1 ROP were treated with one 0.625-mg intravitreal injection of bevacizumab. Disease in all eyes regressed with no need for additional treatment, she said.

As a primary treatment, anti-VEGF therapy resulted in less retinal destruction and better refractive outcomes than with laser, she said.

However, anti-VEGF treatments should be used as an adjunct when performing ROP retinal detachment surgery, she said. Additionally, for progressive ROP cases, anti-VEGF should be used preoperatively in ROP retinal surgery procedures to reduce vascular activity at follow-up, she said. – by Robert Linnehan


Dorta P. New therapies for retinopathy of prematurity (ROP). Presented at: Retina World Congress; Feb. 23-26, 2017; Fort Lauderdale, Fla.

Disclosure: Dorta reports no relevant financial disclosures.